- Messages
- 1,043
It is all about FAD and NADPH. not just NADPH. they recycle glutathione . pyridoxine is activated by FAD or zinc. so it is about pyridoxine. this is why I give b1 and b2. and b6 This will convert tryptophan to niacin with zero problems, chelate iron( if you have it high) , retain potassium and increase NADPH.
NADPH oxidase will be activated when there is no potassium. So potassium is important along with magnesium
In chizo there is high dopamine, since ascorbate is not recycled by glutathione. You need Fad and NADPH for that.
It is all about the balance of FAD with NADPH. One makes another work.
if there is no NADPH , FAD wont be available either, since NADPH oxidase = FAD enzyme.
Riboflavin + NADPH= reduced ribo
And b6 active( which is fad or zinc) wont be working if there is no histidine, or there is high histamine. Since they convert histidine into histamine.
This is why B2 is needed to convert folates into methylfolate. since it activates b6. Methylfolate will lower histamine, and if you have low histamine already. this will lower your copper.
And if you give b2 without b1. you will increase histamines and have crazy intercellular histamines. And lower intracellular histamine since b2 is also in DAO ( since dao needs active b6 which is b2 and zinc)This is why in really bad histamine cases, you give b2 with methylfolate for a short time. along with all other bs and b1 and then you take away methylfolate. Methylfolate is to clear intercellular histamines basically substituting b1, and to speed up B2 availability which increases active b6 to produce more histamine and methylfolate.
We were talking about the markers how to see NADPH activity , but we need to look for the markers to see FAD and NADPH activity.
but overall, IDO TDO pathway is what matters also, some have it activated and some have the problems to activate it. And it is all about iron b2 ( b6) for this pathway.
To make NADPH you need NAD, pentose and phosphorus. to make NAD you need iron and b2.( b6)
But there are 100s of regulations of all this stuff, that is why it is so hard to lift up, since if you dont account for one connected thing, it does not work.
Androgens induce NADPH oxidase. since androgens lower potassium. After looking at @Yura it is understandable why he saw crazy oxidives stress and losing his elastic tissue. May be even heart tissue. SO androgens are not good IMO.This is why we need to look at the balance of B vitamins here. And see which ones we are missing.
Actually in pyroluria they give zinc and b6. Those are lost in the urine. And people are wondering why are those lost in the urine.
Since glutathione is not working. And zinc and b6 will make histamine. And there is no methyl folate without glutathione to get rid of histamine intercellular.
So we have 2 histamines intra and intercelluar. intra is taken care off by DAO which is copper and active b6 and histidine.and intercellular is taken care of by methylfolate. So obviously for the methylation to work, you need to have histamine made) And some blocks in the methylation will be because of lack of histidine also.
B6 can be activated by B2 or zinc. 2 different enzymes. So If you have low methylfolate because of low FAD. then you cant get rid of histamine. And body has to lower zinc and b6 and puts it into the urine.( and this is called pyroluria). since if it does not , then people have anxiety , since their intercellur histamines are too high. These people never really recover on zinc and b6. Since that will never increase their FAD.
SO I would assume it is more of a FAD( NAPDH) deficiency which causes zinc and B6 to be out, in pyroluria.
Hoffer cured schizo with huge doses of niacin. Basically lowering intercellular histamines .( which is what schizo is) dopamine thing is a part of it. the oxidative stress kills cerebellum , it gets smaller and smaller and smaller. So schizo is basically oxidative stress disease
And it kills cerebellum by oxidation and actually there isnt enough NDMA action there which ruins GABA reception. And slowly gaba goes down. since GABA itself ruins KCC2 transporter I would assume.
The role of the cerebellum in schizophrenia: from cognition to molecular pathways
I love that you are here on this forum Helen. Your input is fantastic!
Let's not also forget that NADPH and Kynurenic Acids have a strong interaction.
NADPH tends to downregulate the IDO/Kynurenic acid pathway and vice-versa.
Allowing for "stabilized" NMDAR and Glutamate activity.
On the other hand, moving too far in that direction and suppressing Kynurenic acid TOO MUCH will surely lead to MORE Oxidative Stress.
Deregulated tryptophan-kynurenine pathway is linked to inflammation, oxidative stress, and immune activation pathway in cardiovascular diseases. (PubMed)
...Of other interest the Phosphate Cycle; a key ingredient in TOXICITY is also regulated by similar pathways.
Kynurenic Acid: The Janus-Faced Role of an Immunomodulatory Tryptophan Metabolite and Its Link to Pathological Conditions. [Frontiers in Immunology]
Schizophr Bull. 2017 Jul 1;43(4):764-777. doi: 10.1093/schbul/sbw221.
Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysis.
Plitman E1,2, Iwata Y1, Caravaggio F1, Nakajima S1,3,4,5, Chung JK1,2, Gerretsen P1,3,4, Kim J1,2, Takeuchi H3,5,6, Chakravarty MM7,8, Remington G2,3,6,9, Graff-Guerrero A1,2,3,4,9.
Author information
Abstract
Kynurenic acid (KYNA) is an endogenous antagonist of N-methyl-D-aspartate and α7 nicotinic acetylcholine receptors that is derived from astrocytes as part of the kynurenine pathway of tryptophan degradation. Evidence suggests that abnormal KYNA levels are involved in the pathophysiology of schizophrenia. However, this has never been assessed through a meta-analysis. A literature search was conducted through Ovid using Embase, Medline, and PsycINFO databases (last search: December 2016) with the search terms: (kynuren* or KYNA) and (schizophreni* or psychosis). English language studies measuring KYNA levels using any method in patients with schizophrenia and healthy controls (HCs) were identified. Standardized mean differences (SMDs) were calculated to determine differences in KYNA levels between groups. Subgroup analyses were separately performed for nonoverlapping participant samples, KYNA measurement techniques, and KYNA sample source. The influences of patients' age, antipsychotic status (%medicated), and sex (%male) on study SMDs were assessed through a meta-regression. Thirteen studies were deemed eligible for inclusion in the meta-analysis. In the main analysis, KYNA levels were elevated in the patient group. Subgroup analyses demonstrated that KYNA levels were increased in nonoverlapping participant samples, and centrally (cerebrospinal fluid and brain tissue) but not peripherally. Patients' age, %medicated, and %male were each positively associated with study SMDs. Overall, KYNA levels are increased in patients with schizophrenia, specifically within the central nervous system. An improved understanding of KYNA in patients with schizophrenia may contribute to the development of novel diagnostic approaches and therapeutic strategies.
KEYWORDS:
kynurenine; neuroinflammation; psychosis; tryptophan
PMID: 28187219 PMCID: PMC5472151 DOI: 10.1093/schbul/sbw221
Last edited: